Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond

Journal of the American College of Cardiology

Volumn 70, Issue 18, 2017, Pages 2278-2289

  Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndromes; high sensitivity C reactive protein; interleukin 1; myocardial infarction

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ANAKINRA; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CANAKINUMAB; CD40 ANTIGEN; COLCHICINE; DARAPLADIB; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LOSMAPIMOD; LOW DENSITY LIPOPROTEIN; METHOTREXATE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; TOCILIZUMAB; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; GOUT; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MUCKLE WELLS SYNDROME; NONHUMAN; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BIOMARKERS; DRUG DELIVERY SYSTEMS; HUMANS; INTERLEUKIN-1BETA;

EID: 85032795855     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.09.028     Document Type: Review

References (122)

1. Libby, P., Inflammatory and immune mechanisms in atherogenesis. Leaf, A., Weber, P., (eds.) Atheroclerosis Reviews, 1990, Raven Press, New York, 79–89.
2. Libby, P., Ridker, P.M., Hansson, G.K., Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54 (2009), 2129–2138.
3. Lichtman, A.H., Binder, C.J., Tsimikas, S., Witztum, J.L., Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest 123 (2013), 27–36.
4. Hansson, G.K., Libby, P., Tabas, I., Inflammation and plaque vulnerability. J Intern Med 278 (2015), 483–493.
5. Libby, P., Hansson, G.K., Inflammation and immunity in diseases of the arterial tree: players and layers. Circ Res 116 (2015), 307–311.
6. Nus, M., Mallat, Z., Immune-mediated mechanisms of atherosclerosis and implications for the clinic. Expert Rev Clin Immunol 12 (2016), 1217–1237.
7. Weber, C., Shantsila, E., Hristov, M., et al. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) Working Groups “Atherosclerosis and Vascular Biology” and “Thrombosis”. Thromb Haemost, 116, 2016.
8. Libby, P., History of discovery: inflammation in atherosclerosis. Arterioscler Thromb 32 (2012), 2045–2051.
9. Cook, N.R., Paynter, N.P., Eaton, C.B., et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation 125 (2012), 1748–1756 S1741–1711.
10. Ridker, P.M., A Test in Context: High-Sensitivity C-Reactive Protein. J Am Coll Cardiol 67 (2016), 712–723.
11. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
12. Schonbeck, U., Libby, P., Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 109 (2004), II18–II26.
13. Ridker, P.M., Cannon, C.P., Morrow, D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005), 20–28.
14. Jain, M.K., Sangwung, P., Hamik, A., Regulation of an inflammatory disease: Kruppel-like factors and atherosclerosis. Arterioscler Thromb 34 (2014), 499–508.
15. Libby, P., The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 46 (2005), 1225–1228.
16. Jernberg, T., Hasvold, P., Henriksson, M., Hjelm, H., Thuresson, M., Janzon, M., Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 36 (2015), 1163–1170.
17. Masoudi, F.A., Ponirakis, A., de Lemos, J.A., et al. Trends in U.S. cardiovascular care: 2016 report from 4 ACC national cardiovascular data registries. J Am Coll Cardiol 69 (2017), 1427–1450.
18. Dinarello, C.A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117 (2011), 3720–3732.
19. Feldmann, M., Many cytokines are very useful therapeutic targets in disease. J Clin Invest 118 (2008), 3533–3536.
20. Ait-Oufella, H., Taleb, S., Mallat, Z., Tedgui, A., Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb 31 (2011), 969–979.
21. Dinarello, C.A., Demonstration of a human pyrogen-inducing factor during mixed leukocyte reactions. J Exp Med 153 (1981), 1215–1224.
22. Auron, P.E., Webb, A.C., Rosenwasser, L.J., et al. Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci U S A 81 (1984), 7907–7911.
23. Dinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27 (2009), 519–550.
24. Dinarello, C.A., Ikejima, T., Warner, S.J.C., et al. Interleukin-1 induces interleukin-1. I. Induction of circulating interleukin-1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 139 (1987), 1902–1910.
25. Warner, S.J.C., Auger, K.R., Libby, P., Interleukin-1 induces interleukin-1. II. Recombinant human interleukin-1 induces interleukin-1 production by adult human vascular endothelial cells. J Immunol 139 (1987), 1911–1917.
26. Beltrami-Moreira, M., Vromman, A., Sukhova, G.K., Folco, E.J., Libby, P., Redundancy of IL-1 isoform signaling and its implications for arterial remodeling. PLoS One, 11, 2016, e0152474.
27. Geng, Y.-J., Libby, P., Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 β-converting enzyme. Am J Pathol 147 (1995), 251–266.
28. Latz, E., Xiao, T.S., Stutz, A., Activation and regulation of the inflammasomes. Nat Rev Immunol 13 (2013), 397–411.
29. Patel, M.N., Carroll, R.G., Galvan-Pena, S., et al. Inflammasome priming in sterile inflammatory disease. Trends Mol Med 23 (2017), 165–180.
30. Mariathasan, S., Monack, D.M., Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7 (2007), 31–40.
31. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., Tschopp, J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 (2006), 237–241.
32. Duewell, P., Kono, H., Rayner, K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464 (2010), 1357–1361.
33. Rajamaki, K., Lappalainen, J., Oorni, K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One, 5, 2010, e11765.
34. Paramel Varghese, G., Folkersen, L., Strawbridge, R.J., et al. NLRP3 inflammasome expression and activation in human atherosclerosis. J Am Heart Assoc, 5, 2016.
35. Xiao, H., Lu, M., Lin, T.Y., et al. Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation 128 (2013), 632–642.
36. Abe, J., Berk, B.C., Atheroprone flow activation of the sterol regulatory element binding protein 2 and nod-like receptor protein 3 inflammasome mediates focal atherosclerosis. Circulation 128 (2013), 579–582.
37. Folco, E.J., Sukhova, G.K., Quillard, T., Libby, P., Moderate hypoxia potentiates interleukin-1beta production in activated human macrophages. Circ Res 115 (2014), 875–883.
38. Rajamaki, K., Nordstrom, T., Nurmi, K., et al. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J Biol Chem 288 (2013), 13410–13419.
39. Fearon, W.F., Fearon, D.T., Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 117 (2008), 2577–2579.
40. Abbate, A., Van Tassell, B.W., Biondi-Zoccai, G.G., Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events. BioDrugs 26 (2012), 217–233.
41. Bevilacqua, M.P., Pober, J.S., Wheeler, M.E., Cotran, R.S., Gimbrone, M.A.J., Interleukin-1 activation of vascular endothelium effects on procoagulant activity and leukocyte adhesion. Am J Path 121 (1985), 393–403.
42. Libby, P., Ordovàs, J.M., Auger, K.R., Robbins, H., Birinyi, L.K., Dinarello, C.A., Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol 124 (1986), 179–186.
43. Libby, P., Ordovas, J.M., Birinyi, L.K., Auger, K.R., Dinarello, C.A., Inducible interleukin-1 expression in human vascular smooth muscle cells. J Clin Invest 78 (1986), 1432–1438.
44. Libby, P., Warner, S.J.C., Friedman, G.B., Interleukin-1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 88 (1988), 487–498.
45. Loppnow, H., Libby, P., Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin-6. J Clin Invest 85 (1990), 731–738.
46. Le, J.M., Vilcek, J., Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61 (1989), 588–602.
47. Castell, J.V., Gomez-Lechon, M.J., David, M., Fabra, R., Trullenque, R., Heinrich, P.C., Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12 (1990), 1179–1186.
48. Sarwar, N., Butterworth, A.S., Freitag, D.F., et al., for the IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379 (2012), 1205–1213.
49. Hingorani, A.D., Casas, J.P., for the Interleukin-6 receptor mendelian randomisation analysis (IL6R MR) consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379 (2012), 1214–1224.
50. Suzuki, K., Murtuza, B., Smolenski, R.T., et al. Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis. Circulation 104 (2001), I308–I313.
51. Abbate, A., Salloum, F.N., Van Tassell, B.W., et al. Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse. PLoS One, 6, 2011, e27923.
52. Abbate, A., Van Tassell, B.W., Biondi-Zoccai, G., et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 111 (2013), 1394–1400.
53. Abbate, A., Dinarello, C.A., Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?. Eur Heart J 36 (2015), 337–339.
54. Morton, A.C., Rothman, A.M., Greenwood, J.P., et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J 36 (2015), 377–384.
55. Shimokawa, H., Ito, A., Fukumoto, Y., et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest 97 (1996), 769–776.
56. Morton, A.C., Arnold, N.D., Gunn, J., et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. Cardiovasc Res 68 (2005), 493–501.
57. Elhage, R., Maret, A., Pieraggi, M.T., Thiers, J.C., Arnal, J.F., Bayard, F., Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 97 (1998), 242–244.
58. Kirii, H., Niwa, T., Yamada, Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb 23 (2003), 656–660.
59. Chi, H., Messas, E., Levine, R.A., Graves, D.T., Amar, S., Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 110 (2004), 1678–1685.
60. Merhi-Soussi, F., Kwak, B.R., Magne, D., et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 66 (2005), 583–593.
61. Nicklin, M.J., Hughes, D.E., Barton, J.L., Ure, J.M., Duff, G.W., Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 191 (2000), 303–312.
62. Isoda, K., Kitagaki, M., Niida, T., et al. Deficiency of interleukin-1 receptor antagonist promotes spontaneous femoral artery aneurysm formation in mice. Am J Pathol 180 (2012), 1254–1263.
63. Isoda, K., Sawada, S., Ishigami, N., et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb 24 (2004), 1068–1073.
64. Alexander, M.R., Moehle, C.W., Johnson, J.L., et al. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 122 (2012), 70–79.
65. Hawrylowicz, C.M., Santoro, S.A., Platt, F.M., Unanue, E.R., Activated platelets express IL-1 activity. J Immunol 143 (1989), 4015–4018.
66. Brown, G.T., McIntyre, T.M., Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles. J Immunol 186 (2011), 5489–5496.
67. Rader, D.J., IL-1 and atherosclerosis: a murine twist to an evolving human story. J Clin Invest 122 (2012), 27–30.
68. Dinarello, C.A., Simon, A., van der Meer, J.W., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11 (2012), 633–652.
69. Van Tassell, B.W., Toldo, S., Mezzaroma, E., Abbate, A., Targeting interleukin-1 in heart disease. Circulation 128 (2013), 1910–1923.
70. Hong, D.S., Janku, F., Naing, A., et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs 33 (2015), 621–631.
71. Lachmann, H.J., Kone-Paut, I., Kuemmerle-Deschner, J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 (2009), 2416–2425.
72. Ruperto, N., Brunner, H.I., Quartier, P., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2396–2406.
73. Schlesinger, N., Alten, R.E., Bardin, T., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71 (2012), 1839–1848.
74. Ridker, P.M., Howard, C.P., Walter, V., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
75. Ridker, P.M., Thuren, T., Zalewski, A., Libby, P., Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162 (2011), 597–605.
76. Ridker, P.M., Everett, B.M., Thuren, T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377 (2017), 1119–1131.
77. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015.
78. Sabatine, M.S., Giugliano, R.P., Keech, A.C., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
79. Ridker, P.M., Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J 37 (2016), 1720–1722.
80. Ridker, P.M., How common is residual inflammatory risk?. Circ Res, 120, 2017, 617.
81. Ridker, P., Informative neutral studies matter—why the targeting inflammation with salsalate in cardiovascular disease (TINSAL-CVD) trial deserves our attention. JAMA Cardiol 1 (2016), 423–424.
82. White, H.D., Held, C., Stewart, R., et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 370 (2014), 1702–1711.
83. O'Donoghue, M.L., Braunwald, E., White, H.D., et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA 312 (2014), 1006–1015.
84. O'Donoghue, M.L., Glaser, R., Aylward, P.E., et al. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J 169 (2015), 622–630.
85. O'Donoghue, M.L., Glaser, R., Cavender, M.A., et al. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: a randomized clinical trial. JAMA 315 (2016), 1591–1599.
86. Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A., Thompson, P.L., Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 61 (2013), 404–410.
87. Tardif J-C, L'Allier P. Colchicine Cardiovascular Outcomes Trial (COLCOT). 2017. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02551094?term=colcot&rank=1. Accessed October 10, 2017.
88. Everett, B.M., Pradhan, A.D., Solomon, D.H., et al. Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166 (2013), 199–207.
89. Hong, D.S., Hui, D., Bruera, E., et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15 (2014), 656–666.
90. Kleveland, O., Kunszt, G., Bratlie, M., et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J 37 (2016), 2406–2413.
91. Mallat, Z., Corbaz, A., Scoazec, A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104 (2001), 1598–1603.
92. Gerdes, N., Sukhova, G.K., Libby, P., Reynolds, R.S., Young, J.L., Schonbeck, U., Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 195 (2002), 245–257.
93. Wang, J., Sun, C., Gerdes, N., et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat Med 21 (2015), 820–826.
94. Toldo, S., Mezzaroma, E., Mauro, A.G., Salloum, F., Van Tassell, B.W., Abbate, A., The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal 22 (2015), 1146–1161.
95. van Hout, G.P., Bosch, L., Ellenbroek, G.H., et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J 38 (2016), 828–836.
96. van der Heijden, T., Kritikou, E., Venema, W., et al. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Arterioscler Thromb 37 (2017), 1457–1461.
97. Mach, F., Schönbeck, U., Sukhova, G.K., et al. Functional CD 40 Ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94 (1997), 1931–1936.
98. Mach, F., Schonbeck, U., Sukhova, G.K., Atkinson, E., Libby, P., Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998), 200–203.
99. Schonbeck, U., Mach, F., Libby, P., CD154 (CD40 ligand). Int J Biochem Cell Biol 32 (2000), 687–693.
100. Lutgens, E., Gorelik, L., Daemen, M.J., et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 5 (1999), 1313–1316.
101. Lutgens, E., Cleutjens, K.B., Heeneman, S., Koteliansky, V.E., Burkly, L.C., Daemen, M.J., Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. [see comments] Proc Natl Acad Sci U S A 97 (2000), 7464–7469.
102. Donner, A.J., Yeh, S.T., Hung, G., Graham, M.J., Crooke, R.M., Mullick, A.E., CD40 generation 2.5 antisense oligonucleotide treatment attenuates doxorubicin-induced nephropathy and kidney inflammation. Mol Ther Nucleic Acids, 4, 2015, e265.
103. Zarzycka, B., Seijkens, T., Nabuurs, S.B., et al. Discovery of small molecule CD40-TRAF6 inhibitors. J Chem Inf Model 55 (2015), 294–307.
104. Warner, S.J., Libby, P., Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol 142 (1989), 100–109.
105. Silva, L.C., Ortigosa, L.C., Benard, G., Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2 (2010), 817–833.
106. Gu, L., Okada, Y., Clinton, S., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol Cell 2 (1998), 275–281.
107. Gosling, J., Slaymaker, S., Gu, L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999), 773–778.
108. Boring, L., Gosling, J., Cleary, M., Charo, I.F., Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998), 894–897.
109. Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., et al. Nomenclature of monocytes and dendritic cells in blood. Blood 116 (2010), e74–e80.
110. Swirski, F.K., Nahrendorf, M., Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339 (2013), 161–166.
111. Libby, P., Nahrendorf, M., Swirski, F.K., Leukocytes link local and systemic inflammation in ischemic cardiovascular disease. J Am Coll Cardiol 67 (2016), 1091–1103.
112. Swirski, F.K., Nahrendorf, M., Libby, P., Mechanisms of myeloid cell modulation of atherosclerosis. Microbiol Spectr, 4(4), 2016.
113. Ridker, P.M., MacFadyen, J.G., Thuren, T., et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 2017 Aug 25 [E-pub ahead of print].
114. Dinarello, C.A., Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev 29 (2010), 317–329.
115. Galis, Z., Muszynski, M., Sukhova, G., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75 (1994), 181–189.
116. Li, H.J., Reinhardt, F., Herschman, H.R., Weinberg, R.A., Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov 2 (2012), 840–855.
117. Sager, H.B., Heidt, T., Hulsmans, M., et al. Targeting Interleukin-1beta Reduces Leukocyte Production After Acute Myocardial Infarction. Circulation 132 (2015), 1880–1890.
118. Sager, H.B., Dutta, P., Dahlman, J.E., et al. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci Transl Med, 8, 2016, 342ra80.
119. Libby, P., Murine “model” monotheism: an iconoclast at the altar of mouse. Circ Res 117 (2015), 921–925.
120. Warner, S.J.C., Auger, K.R., Libby, P., Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med 165 (1987), 1316–1331.
121. Loppnow, H., Libby, P., Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol 122 (1989), 493–503.
122. Schoenbeck, U., Mach, F., Bonnefoy, J.Y., Loppnow, H., Flad, H.D., Libby, P., Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta. J Biol Chem 272 (1997), 19569–19574.